OBJECTIVE: Previous data, based on a small sampling of convenience, reported subtypes A, B, C, D, and G in Uganda, but neither the extent nor the proportion of these subtypes could be evaluated. To establish correctly the prevalence and distribution of HIV-1 subtypes, we analysed viral clades in 739 HIV-1-seropositive specimens from different areas of Uganda. METHODS: Blood specimens from 1100 patients were collected in five districts of Uganda. Within this collection, 929 HIV-1-seroreactive samples underwent analysis of viral DNA, and 739 were selected for further subtyping in env or pol regions. RESULTS: Using a combination of subtype A- and D-specific probes to C2-V3 region and DNA sequencing, HIV-1 env subtypes were determined in 594 specimens: 341 were of subtype A (57.4%), 250 of subtype D (42.1%), and three of subtype C (0.5%). Sixty-two samples showed reactivity with both probes, suggesting potential mixed infections, cross-reactivity to probes, or possibly other subtypes. Subsequent sequence analysis of 19 randomly selected specimens revealed subtypes A (n = 4), D (n = 12), and C (n = 3). Sequence analysis of the 27 samples chosen from the remaining 83 samples, which could be amplified only with viral gp41 or protease gene primers, classified them as subtypes A (n = 13) and D (n = 14). No significant clinical, demographic, or geographic differences were found between HIV-1 infections with viruses of subtypes A and D, despite considerable genetic diversity within these clades. CONCLUSIONS: This is the first major population-based study of the prevalent HIV-1 strains in an African country selected for vaccine trials. The subtyping methods we describe should be of use to investigators seeking to conduct large-scale screening for HIV variants in other populations.
OBJECTIVE: Previous data, based on a small sampling of convenience, reported subtypes A, B, C, D, and G in Uganda, but neither the extent nor the proportion of these subtypes could be evaluated. To establish correctly the prevalence and distribution of HIV-1 subtypes, we analysed viral clades in 739 HIV-1-seropositive specimens from different areas of Uganda. METHODS: Blood specimens from 1100 patients were collected in five districts of Uganda. Within this collection, 929 HIV-1-seroreactive samples underwent analysis of viral DNA, and 739 were selected for further subtyping in env or pol regions. RESULTS: Using a combination of subtype A- and D-specific probes to C2-V3 region and DNA sequencing, HIV-1env subtypes were determined in 594 specimens: 341 were of subtype A (57.4%), 250 of subtype D (42.1%), and three of subtype C (0.5%). Sixty-two samples showed reactivity with both probes, suggesting potential mixed infections, cross-reactivity to probes, or possibly other subtypes. Subsequent sequence analysis of 19 randomly selected specimens revealed subtypes A (n = 4), D (n = 12), and C (n = 3). Sequence analysis of the 27 samples chosen from the remaining 83 samples, which could be amplified only with viral gp41 or protease gene primers, classified them as subtypes A (n = 13) and D (n = 14). No significant clinical, demographic, or geographic differences were found between HIV-1 infections with viruses of subtypes A and D, despite considerable genetic diversity within these clades. CONCLUSIONS: This is the first major population-based study of the prevalent HIV-1 strains in an African country selected for vaccine trials. The subtyping methods we describe should be of use to investigators seeking to conduct large-scale screening for HIV variants in other populations.
Authors: Susan H Eshleman; Matthew J Gonzales; Graziella Becker-Pergola; Shawn C Cunningham; Laura A Guay; J Brooks Jackson; Robert W Shafer Journal: AIDS Res Hum Retroviruses Date: 2002-05-01 Impact factor: 2.205
Authors: Elvin H Geng; Torsten B Neilands; Rodolphe Thièbaut; Mwebesa Bosco Bwana; Denis Nash; Richard D Moore; Robin Wood; Djimon Marcel Zannou; Keri N Althoff; Poh Lian Lim; Jean B Nachega; Philippa J Easterbrook; Andrew Kambugu; Francesca Little; Gertrude Nakigozi; Damalie Nakanjako; Valerian Kiggundu; Patrick Chung Ki Li; David R Bangsberg; Matthew P Fox; HansW Prozesky; Peter W Hunt; Mary-Ann Davies; Steven J Reynolds; Matthias Egger; Constantin T Yiannoutsos; Eric V Vittinghoff; Steven G Deeks; Jeffrey N Martin Journal: Int J Epidemiol Date: 2015-02 Impact factor: 7.196
Authors: M Mracna; G Becker-Pergola; J Dileanis; L A Guay; S Cunningham; J B Jackson; S H Eshleman Journal: J Clin Microbiol Date: 2001-12 Impact factor: 5.948
Authors: Grace P McCormack; Judith R Glynn; Amelia C Crampin; Felix Sibande; Dominic Mulawa; Lyn Bliss; Philip Broadbent; Katia Abarca; Jorg M Pönnighaus; Paul E M Fine; Jonathan P Clewley Journal: J Virol Date: 2002-12 Impact factor: 5.103
Authors: N Vidal; M Peeters; C Mulanga-Kabeya; N Nzilambi; D Robertson; W Ilunga; H Sema; K Tshimanga; B Bongo; E Delaporte Journal: J Virol Date: 2000-11 Impact factor: 5.103
Authors: Susan H Eshleman; Oliver Laeyendecker; Neil Parkin; Wei Huang; Colombe Chappey; Agnes C Paquet; David Serwadda; Steven J Reynolds; Noah Kiwanuka; Thomas C Quinn; Ronald Gray; Maria Wawer Journal: AIDS Date: 2009-04-27 Impact factor: 4.177